Alurar rigakafin typhoid alluran rigakafi ne da ke hana zazzabin typhoid. Akwai nau'o'i da yawa: maganin typhoid conjugate (TCV), Ty21a (alurar rigakafi mai rai ) da Vi capsular polysaccharide (ViPS) ( alurar riga- kafi).[1] Suna da kusan kashi 30 zuwa 70% masu tasiri a cikin shekaru biyu na farko, ya danganta da takamaiman maganin da ake tambaya. An nuna maganin rigakafin Vi-rEPA yana da amfani ga yara. maganan gaskin gyaran ne ake tayi dimin samun damar.

Alurar rigakafin typhoid
essential medicine (en) Fassara da vaccine type (en) Fassara
Bayanai
Ƙaramin ɓangare na typhoid-paratyphoid vaccines (en) Fassara
Vaccine for (en) Fassara Zazzabin Rawaya
WordLift URL (en) Fassara http://data.medicalrecords.com/medicalrecords/healthwise/typhoid_vaccines__what_you_need_to_know

Amfanin likitanci gyara sashe

Ty21a, maganin Vi capsular polysaccharide, da Vi-rEPA suna da tasiri wajen rage zazzaɓin typhoid tare da ƙananan sakamako masu illa. Sabbin alluran rigakafi irin su Vi-TT (PedaTyph) suna jiran [yaushe?] gwaje-gwajen filin don nuna inganci a kan fallasa na halitta. Alurar rigakafi ta baka ta Ty21a tana hana kusan rabin cututtukan taifot a cikin shekaru uku na farko bayan alurar riga kafi.[2] Alurar rigakafin Vi polysaccharide mai allura ya hana kusan kashi biyu bisa uku na cututtukan typhoid a cikin shekara ta farko kuma yana da ingantaccen tasiri na 55% a shekara ta uku. An nuna ingancin waɗannan alluran rigakafin a cikin yara waɗanda suka wuce shekaru biyu kawai. Alurar rigakafin Vi-rEPA, sabon nau'i na haɗin gwiwa na allurar Vi, na iya zama mafi inganci kuma yana hana cutar a yawancin yara 'yan ƙasa da shekaru biyar. A cikin gwaji a cikin yara masu shekaru 2 zuwa 5 a Vietnam, maganin yana da inganci fiye da kashi 90 cikin ɗari a cikin shekara ta farko kuma kariya ta ɗauki akalla shekaru huɗu.[3]

Jadawalin gyara sashe

Dangane da tsarin za a iya ba da shi tun yana ɗan shekara biyu (ViPS), shida (Ty21a), ko wata shida (TCV)[3][4]

Manazarta gyara sashe

  1. World Health Organization (2018). "Typhoid vaccines: WHO position paper – March 2018". Weekly Epidemiological Record. 93 (13): 153–172. hdl:10665/272273.
  2. World Health Organization (2019). "Typhoid vaccines: WHO position paper, March 2018 - Recommendations". Vaccine. 37 (2): 214–216. doi:10.1016/j.vaccine.2018.04.022. PMID 29661581. S2CID 4902671.
  3. 3.0 3.1 "Summary of the WHO Position Paper on Typhoid vaccines: WHO position paper – March 2018" (PDF). origin.who.int. October 23, 2019. Archived from the original (PDF) on October 23, 2019.
  4. World Health Organization (2019). "Typhoid vaccines: WHO position paper, March 2018 - Recommendations". Vaccine. 37 (2): 214–216. doi:10.1016/j.vaccine.2018.04.022. PMID 29661581. S2CID 4902671.